Answers are grounded in this paper and cite their sources.
DACRAs complement GLP-1 on food intake, body weight, and glucose tolerance indicating the potential for an add-on therapy.
No takes yet. Share an insight, caveat, or question.
Larsen et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: